OphtiMedRx LTD is an ophthalmic drug development company supported by Galil Ofek Ventures, Mor Research Applications, and RunYoung organization. The company is developing a novel innovative molecular pharmacotherapy for dry Age-related Macular Degeneration (AMD), a common eye disease leading to blindness with a multi-billion USD market opportunity.